3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Leukemia, Myeloid, Acute
5
Neoplasms
3
Carcinoma, Non-Small-Cell Lung
2
Recurrence
1
Plasmacytoma
1
Pathologic Complete Response
1
Pancreatic Neoplasms
1
Neoplasm Metastasis
1
Nasopharyngeal Neoplasms
1
Nasopharyngeal Carcinoma
1
Myeloid Malignancies
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Microsatellite Stable Colorectal Carcinoma
1
Lung Neoplasms
1
Leukemia, Myelomonocytic, Chronic
1
Hematologic Neoplasms
1
Hematologic Diseases
1
Head and Neck Neoplasms
1
Epstein-Barr Virus Infections
1
Carcinoma, Ovarian Epithelial
1
Breast Neoplasms
1
Interventions
Carboplatin
195
Cisplatin
117
Paclitaxel
107
Pemetrexed
106
Docetaxel
96
Gemcitabine
89
Radiotherapy
83
Erlotinib Hydrochloride
58
Bevacizumab
55
Etoposide
49
durvalumab
39
pembrolizumab
38
Nivolumab
31
Specimen Handling
30
Magnetic Resonance Spectroscopy
30
Irinotecan
27
Radiosurgery
26
osimertinib
24
Gefitinib
24
Drug Therapy
23
Vinorelbine
22
atezolizumab
20
Topotecan
20
Radiation
16
Cetuximab
16
Taxes
15
Surgical Procedures, Operative
14
Neoadjuvant Therapy
13
Filgrastim
13
Chemotherapy, Adjuvant
13
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Lung Neoplasms
×
cc-486
×
Clear all
NCT02250326
2024-09-19
abound2L+
Celgene
Phase 2
Completed
240 enrolled
23 charts